CAR T-Cell Therapy Holds Promise for Multiple Myeloma
at
Cellular immunotherapies such as chimeric antigen receptor therapy are a promising approach for treatment of multiple myeloma. CAR T-cells have impressive activity against leukemia and lymphoma, and this has encouraged development of these therapies for myeloma, James N. Kochenderfer, MD, physician-scientist at Center for Cancer Research at NCI, said during his presentation.